Literature DB >> 33467389

Immune Therapies for Hematologic Malignancies.

Matthew J Olnes1,2.   

Abstract

The era of immunotherapy for hematologic malignancies began with the first allogeneic hematopoietic stem cell transplant (HSCT) study published by E [...].

Entities:  

Year:  2021        PMID： 33467389      PMCID： PMC7829785          DOI： 10.3390/cancers13020295

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN： 2072-6694            Impact factor:   6.639


  51 in total

1.  Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Authors:  Noopur Raje; Jesus Berdeja; Yi Lin; David Siegel; Sundar Jagannath; Deepu Madduri; Michaela Liedtke; Jacalyn Rosenblatt; Marcela V Maus; Ashley Turka; Lyh-Ping Lam; Richard A Morgan; Kevin Friedman; Monica Massaro; Julie Wang; Greg Russotti; Zhihong Yang; Timothy Campbell; Kristen Hege; Fabio Petrocca; M Travis Quigley; Nikhil Munshi; James N Kochenderfer
Journal:  N Engl J Med       Date:  2019-05-02       Impact factor: 91.245

2.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Authors:  Sagar Lonial; Meletios Dimopoulos; Antonio Palumbo; Darrell White; Sebastian Grosicki; Ivan Spicka; Adam Walter-Croneck; Philippe Moreau; Maria-Victoria Mateos; Hila Magen; Andrew Belch; Donna Reece; Meral Beksac; Andrew Spencer; Heather Oakervee; Robert Z Orlowski; Masafumi Taniwaki; Christoph Röllig; Hermann Einsele; Ka Lung Wu; Anil Singhal; Jesus San-Miguel; Morio Matsumoto; Jessica Katz; Eric Bleickardt; Valerie Poulart; Kenneth C Anderson; Paul Richardson
Journal:  N Engl J Med       Date:  2015-06-02       Impact factor: 91.245

3.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.

Authors:  Enli Liu; David Marin; Pinaki Banerjee; Homer A Macapinlac; Philip Thompson; Rafet Basar; Lucila Nassif Kerbauy; Bethany Overman; Peter Thall; Mecit Kaplan; Vandana Nandivada; Indresh Kaur; Ana Nunez Cortes; Kai Cao; May Daher; Chitra Hosing; Evan N Cohen; Partow Kebriaei; Rohtesh Mehta; Sattva Neelapu; Yago Nieto; Michael Wang; William Wierda; Michael Keating; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  N Engl J Med       Date:  2020-02-06       Impact factor: 91.245

4.  Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.

Authors:  H Miles Prince; Youn H Kim; Steven M Horwitz; Reinhard Dummer; Julia Scarisbrick; Pietro Quaglino; Pier Luigi Zinzani; Pascal Wolter; Jose A Sanches; Pablo L Ortiz-Romero; Oleg E Akilov; Larisa Geskin; Judith Trotman; Kerry Taylor; Stephane Dalle; Michael Weichenthal; Jan Walewski; David Fisher; Brigitte Dréno; Rudolf Stadler; Tatyana Feldman; Timothy M Kuzel; Yinghui Wang; Maria Corinna Palanca-Wessels; Erin Zagadailov; William L Trepicchio; Wenwen Zhang; Hui-Min Lin; Yi Liu; Dirk Huebner; Meredith Little; Sean Whittaker; Madeleine Duvic
Journal:  Lancet       Date:  2017-06-07       Impact factor: 79.321

5.  Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.

Authors:  Robin Foà; Renato Bassan; Antonella Vitale; Loredana Elia; Alfonso Piciocchi; Maria-Cristina Puzzolo; Martina Canichella; Piera Viero; Felicetto Ferrara; Monia Lunghi; Francesco Fabbiano; Massimiliano Bonifacio; Nicola Fracchiolla; Paolo Di Bartolomeo; Alessandra Mancino; Maria-Stefania De Propris; Marco Vignetti; Anna Guarini; Alessandro Rambaldi; Sabina Chiaretti
Journal:  N Engl J Med       Date:  2020-10-22       Impact factor: 91.245

6.  Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.

Authors:  Gilles Salles; Johannes Duell; Eva González Barca; Olivier Tournilhac; Wojciech Jurczak; Anna Marina Liberati; Zsolt Nagy; Aleš Obr; Gianluca Gaidano; Marc André; Nagesh Kalakonda; Martin Dreyling; Johannes Weirather; Maren Dirnberger-Hertweck; Sumeet Ambarkhane; Günter Fingerle-Rowson; Kami Maddocks
Journal:  Lancet Oncol       Date:  2020-06-05       Impact factor: 41.316

Review 7.  Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.

Authors:  Kathryn S Ivy; P Brent Ferrell
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

8.  Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.

Authors:  Max S Topp; Johannes Duell; Gerhard Zugmaier; Michel Attal; Philippe Moreau; Christian Langer; Jan Krönke; Thierry Facon; Alexey V Salnikov; Robin Lesley; Karl Beutner; James Kalabus; Erik Rasmussen; Kathrin Riemann; Alex C Minella; Gerd Munzert; Hermann Einsele
Journal:  J Clin Oncol       Date:  2020-01-02       Impact factor: 44.544

Review 9.  Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.

Authors:  Mark P Chao; Chris H Takimoto; Dong Dong Feng; Kelly McKenna; Phung Gip; Jie Liu; Jens-Peter Volkmer; Irving L Weissman; Ravindra Majeti
Journal:  Front Oncol       Date:  2020-01-22       Impact factor: 6.244

10.  Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

Authors:  Philippe Armand; Andreas Engert; Anas Younes; Michelle Fanale; Armando Santoro; Pier Luigi Zinzani; John M Timmerman; Graham P Collins; Radhakrishnan Ramchandren; Jonathon B Cohen; Jan Paul De Boer; John Kuruvilla; Kerry J Savage; Marek Trneny; Margaret A Shipp; Kazunobu Kato; Anne Sumbul; Benedetto Farsaci; Stephen M Ansell
Journal:  J Clin Oncol       Date:  2018-03-27       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.